Menu

A new CBO analysis estimated that the GOP-backed federal reconciliation package's language that delays or exempts certain orphan drugs from Medicare drug price negotiations could cost $8.8 billion over the next decade.

CBO Estimates Reconciliation Act’s Orphan Drug Medicare Negotiation Exemption Could Cost $8.8 Billion

October 23, 2025 Shannon Young, Associate Editor/Senior Writer 340B Report Views

Language included in the recently enacted GOP-backed federal reconciliation package that delays or exempts certain orphan drugs from Medicare drug [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Shannon Young

GSK Exempts Oklahoma from 340B Contract Pharmacy Restrictions

Large Health Systems Sue HRSA Over ‘Unreasonable Delay’ in 340B Administrative Dispute Resolution Review